Lesson plan

ZMapp

s. To make ZMapp, the genes encoding for the antibodies were extracted from the hybridomas, genetically engineered to replace mouse components with human components, and transfected into tobacco plants. ZMapp is an experimental biopharmaceutical medication comprising three chimeric monoclonal antibodies under development as a treatment for Ebola virus disease. Two of the three components were originally developed at the Public Health Agency of Canada's National Microbiology Laboratory (NML), and the third at the U.S. Army Medical Research Institute of Infectious Diseases; the cocktail was optimized by Gary Kobinger, a research scientist at the NML and underwent further development under license by Mapp Biopharmaceutical. ZMapp was first used on humans during the Western African Ebola virus epidemic, having only been previously tested on animals and not yet subjected to a randomized controlled trial. The National Institutes of Health (NIH) ran a clinical trial starting in January 2015 with 72 subjects from Sierra Leone, Guinea, and Liberia. It had aimed to enroll 200 people, but the epidemic waned and the trial closed early, leaving it too statistically underpowered to give a meaningful result about whether ZMapp worked.

Back to article

Article summary

s. To make ZMapp, the genes encoding for the antibodies were extracted from the hybridomas, genetically engineered to replace mouse components with human components, and transfected into tobacco plants. ZMapp is an experimental biopharmaceutical medication comprising three chimeric monoclonal antibodies under development as a treatment for Ebola virus disease. Two of the three components were originally developed at the Public Health Agency of Canada's National Microbiology Laboratory (NML), and the third at the U.S. Army Medical Research Institute of Infectious Diseases; the cocktail was optimized by Gary Kobinger, a research scientist at the NML and underwent further development under license by Mapp Biopharmaceutical. ZMapp was first used on humans during the Western African Ebola virus epidemic, having only been previously tested on animals and not yet subjected to a randomized controlled trial. The National Institutes of Health (NIH) ran a clinical trial starting in January 2015 with 72 subjects from Sierra Leone, Guinea, and Liberia. It had aimed to enroll 200 people, but the epidemic waned and the trial closed early, leaving it too statistically underpowered to give a meaningful result about whether ZMapp worked.

Key claims

  1. publication date: 2012 — source: Wikipedia, revision 1369645458, retrieved 2026-10-20 · confidence 0.95
  2. publication date: 2013 — source: Wikipedia, revision 1369645458, retrieved 2026-10-20 · confidence 0.95
  3. publication date: 2014 — source: Wikipedia, revision 1369645458, retrieved 2026-10-20 · confidence 0.95
  4. release date: 2014 — source: Wikipedia, revision 1369645458, retrieved 2026-10-20 · confidence 0.95

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. The record states that the publication date is "2012". What evidence would count against this claim?
  3. The record states that the publication date is "2013". What evidence would count against this claim?
  4. The record states that the publication date is "2014". What evidence would count against this claim?
  5. The record states that the release date is "2014". What evidence would count against this claim?
  6. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  7. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

  1. Wikipedia, “ZMapp”, revision 1369645458, retrieved 2026-10-20 https://en.wikipedia.org/w/index.php?oldid=1369645458

Key claims and bibliography are generated from the same tracked claims and sources as the article page.